• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Pregnancy and Postpartum Course
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Access Purchased Content
Home » Topics » General Psychiatry

General Psychiatry
General Psychiatry RSS Feed RSS

Does Brintellix Bring Anything New?

November 1, 2013
Steve Balt, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Steve Balt, MD Research fellow, Addiction Pharmacology Research Laboratory, California Pacific Medical Center Dr. Balt discloses that his spouse is employed as a sales representative for Bristol Myers Squibb.
After a dry spell of new antidepressants—the last one to be approved was levomilnacipran (Fetzima), the active enantiomer of milnacipran (Savella) in July 2013—the FDA approved vortioxetine (Brintellix) in September. Vortioxetine is another serotonergic antidepressant. How exactly does it work, and what are its advantages over existing drugs?
Read More

Metformin for Weight Loss in Schizophrenia

November 1, 2013
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Obesity and metabolic impairments are widespread in both psychiatric and non-psychiatric populations. To make matters worse, weight gain, hyperlipidemia, and diabetes are common side effects of the pharmaceuticals we use to treat psychiatric illness.
Read More

Ketamine for Depression

November 1, 2013
Sanjay J Mathew, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Sanjay J Mathew, MD Associate Professor of Psychiatry & Behavioral Sciences, Baylor College of Medicine, Staff Physician, Michael E. Debakey VA Medical Center, Houston, TX Dr. Mathew has disclosed that he has worked as a paid consultant for AstraZeneca, Naurex, Bristol-Myers Squibb, and Roche/Genentech. Dr. Balt has reviewed this interview and found no evidence of bias in this educational activity.
Can a single infusion of ketamine treat depression? Dr Sanjay Mathew explores the buzz around this treatment.
Read More

Learning Objectives, Depression, TCPR, November 2013

November 1, 2013
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
After reading these articles, you should be able to…
Read More

Current Pharmacological Treatment of Dementia

October 1, 2013
Cary S. Gunther, PhD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Cary S. Gunther, PhD Neurologist and psychiatrist in private practice, Voluntary Faculty, New York Presbyterian-Weill Cornell Medical Center Dr. Gunther has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Patients with dementia and their families may express frustration about the limited number of options for improving cognitive symptoms, but they are not without choices. Here we will review a number of pharmacological treatment options for Alzheimer’s disease (AD) and other major types of dementia.
Read More

Table - Types of Dementia

October 1, 2013
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Documents: Table - Types of Dementia.pdf...
Read More

Psychiatric Illness in the Elderly

October 1, 2013
Dan G. Blazer, PhD, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Dan G. Blazer, PhD, MD Vice Chair, Department of Psychiatry and Behavioral Sciences, Vice Chair, Academic Development, Duke University Dr. Blazer has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Duke University’s Dr. Dan Blazer explains special considerations for treating psychiatric disorders in the elderly.
Read More

A Blood Test for Suicide?

October 1, 2013
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Prediction of suicidal behavior has long been considered more of an art than a science, although the use of clinical and demographic features can help improve risk assessment. An accurate biological test or “biomarker” for suicidality would be valuable, and a recent study takes us one step closer to that goal.
Read More

APA Warns Against Common Uses of Antipsychotics

October 1, 2013
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
In September, the American Psychiatric Association (APA) released a list of common, but potentially dangerous and inappropriate, uses for antipsychotics.
Read More

Vortioxetine (Brintellix) approved for MDD

October 1, 2013
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue

The FDA has approved vortioxetine (Brintellix) for the treatment of major depressive disorder (MDD). Brintellix is a novel antidepressant thought to work by enhancing serotonergic acitivty as a serotonin (5-HT) reuptake inhibitor and agonist of the 5-HT1A receptor, among other mechanisms.


Read More
Previous 1 2 … 99 100 101 102 103 104 105 106 107 … 178 179 Next
Carlat Total Access Subscriptions: Get access to every article on the website.

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • MFB7e_Print_App_Access.png

    Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

    The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
    READ MORE
Featured Video
  • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
    General Psychiatry

    KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

    Read More
Featured Podcast
  • shutterstock_2637648401.jpg
    General Psychiatry

    Psychopharm Secrets: Coming Off Meds

    There’s a hidden placebo response to watch for when patients stop meds on their own.
    Listen now
Recommended
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report
  • The Carlat Psychotherapy Report

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.